Malign Melanoma with Bone Marrow Involvement: A Case Report

Yıldırım, İbrahim; Saygılı, Özcan; Taşlı, Ayşe Temizel; Sarkisla, Nurbuke; Çakar, Sedef; Güven, Eşref Oğuz; Yükrük, Fisun Ardıç; Canpolat, Ömer

doi:10.5505/aot.2019.46330

Cited by 1 publication

(2 citation statements)

References 5 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 and Table 1, respectively. The included studies were published from 1941 to date [1,2,4–74], with a peak between 2013 and 2023 (60%; 44/73).…”

Section: Resultsmentioning

confidence: 99%

“…In this comprehensive systematic review spanning from 1941 to 21 August 2023, we have meticulously analyzed a total of 73 studies encompassing 146 patients with BMM arising from melanoma with three additional cases of our institutions (San Raffaele Hospital, Milano and Papa Giovanni XXIII Hospital, Bergamo) [1,2,4–74]. Historically, bone marrow involvement in melanoma has been considered a relatively infrequent event, occurring in approximately 5–7% of cases [1,2].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma

Paolino,

Carugno,

Rongioletti

et al. 2023

Melanoma Research

View full text Add to dashboard Cite

The occurrence of bone marrow metastases (BMM) in melanoma patients is often underestimated, with only 7% detected during in-vivo staging procedures but rising to 45% in autopsy cases. This systematic review aims to shed light on the clinical and laboratory features of BMM in melanoma by analyzing 73 studies selected from 2 482 initially retrieved from PubMed, Embase, and Cochrane CENTRAL databases. Our findings reveal a slight male predominance, with a median age at BMM diagnosis of 56 years. Primary melanoma sites included the skin (52%), mucosa (8.8%), uvea (20.5%) and unidentified (19%). BMM was preceded by lymph node involvement in 36.5% of cases, whereas 63% showed no nodal metastases, with direct BMM occurring in 22.5% and metastases to other sites in 41%. Common BMM symptoms included pain (60.7%), anemia (80%), thrombocytopenia, leukoerythroblastosis, pancytopenia and leukopenia, while disseminated intravascular coagulation was detected in 11% of cases. In 23.6% of cases, BMM was amelanotic. The prognosis for BMM is grim, with a median survival of only 2 months. Conventional therapies for BMM remain largely ineffective, emphasizing the importance of considering bone marrow as a potential metastatic site in melanoma patients.

show abstract

“…1 and Table 1, respectively. The included studies were published from 1941 to date [1,2,4–74], with a peak between 2013 and 2023 (60%; 44/73).…”

Section: Resultsmentioning

confidence: 99%